Compare DGICB & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DGICB | EVMN |
|---|---|---|
| Founded | 1986 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.0M | 628.9M |
| IPO Year | N/A | 2025 |
| Metric | DGICB | EVMN |
|---|---|---|
| Price | $17.55 | $17.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 3.5K | ★ 222.7K |
| Earning Date | 02-19-2026 | 02-07-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | ★ 219.91 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $987,826,105.00 | $13,000,000.00 |
| Revenue This Year | $2.26 | $89.43 |
| Revenue Next Year | $3.46 | N/A |
| P/E Ratio | $8.14 | ★ N/A |
| Revenue Growth | 0.89 | ★ 160.00 |
| 52 Week Low | $13.19 | $13.89 |
| 52 Week High | $20.46 | $24.03 |
| Indicator | DGICB | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 59.14 | N/A |
| Support Level | $15.96 | N/A |
| Resistance Level | $17.71 | N/A |
| Average True Range (ATR) | 0.35 | 0.00 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 92.12 | 0.00 |
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.